In relation to making medicine simpler and minimizing uncomfortable side effects, nanomedicine holds a number of promise. In any case, engineered nanoparticles can ship medicine on to diseased cells or tumors and might help corporations develop extra personalised therapies for individuals throughout the globe.
Oncotelic Therapeutics Inc. OTLC, led by CEO Dr. Vuong Trieu who’s an professional within the improvement and regulatory approval of nanomedicine and revolutionary oncology therapeutics, is a part of the vanguard driving the expansion of this discipline.
Trieu, previously President and CEO of Igdrasol, is aware of a factor or two about nanomedicine. Trieu has had an illustrious profession in drug improvement, significantly in nanomedicine and oncology. Previous to creating Igdrasol, the Oncotelic Therapeutics CEO was the Chief Science Officer and Director at Sorrento Therapeutics Inc. The CEO shares that he grew it to a billion-dollar firm earlier than he left, and he has additionally been founder, CEO and government Chairman of Marina Biotech Inc., the RNA-focused biotech. At the moment, as the top of Oncotelic he and his workforce are growing TGF-beta antisense which the corporate says has the potential to remedy each pancreatic most cancers and glioblastoma – among the many deadliest of cancers.
It would not harm that Trieu has over 100 patent purposes and 39 issued patents together with one for Abraxane. Abraxane is a nanoparticle chemotherapy for stable tumors that the corporate says is now an ordinary of look after melanoma, lung, breast and pancreatic cancers. The drug was acquired by Celgene Inc. CELG for $3.9 billion. Celgene was not too long ago acquired by BMS the place Abraxane nonetheless operating at billion-dollar annual gross sales, reviews Oncotelic.
At Igdrasol, Oncotelic shares that Trieu invented Cynviloq, a next-generation Abraxane. Cynviloq was acquired by NantPharma for $1.3 billion, which made Sorrento what it was. At Igdrasol, Trieu shares that he efficiently pioneered the regulatory pathway for paclitaxel-based nanomedicine via a single bioequivalence trial.
At Oncotelic, he has been busy constructing an revolutionary biotechnology firm via numerous subsidiaries and joint ventures. The corporate not too long ago established a state-of-the-art GMP manufacturing facility in San Diego – operated via its three way partnership Sapu Biosciences LLC – which employs superior AI-driven manufacturing applied sciences designed to help the fast improvement of nanomedicine therapeutics. That, says the corporate, ought to considerably bolster its capability to convey novel nanoparticle-based oncology medicine to market.
Groundbreaking Deal With Shanghai Medicilon
Constructing on these efforts, Oncotelic not too long ago inked a cope with Shanghai Medicilon Inc. to hurry up the regulatory approval of medicine in its pipeline for scientific trials. Shanghai Medicilon is a contract analysis group that gives one-stop, built-in analysis and improvement companies to pharmaceutical enterprises and analysis establishments worldwide. The corporate’s platform covers important phases of drug discovery, pharmaceutical analysis and preclinical improvement, striving to streamline drug improvement below worldwide regulatory requirements.
Beneath the collaboration, Oncotelic and its numerous subsidiaries – together with Sapu Bioscience – will make the most of Medicilon’s fast medicines in improvement platform to help as much as 20 Investigational New Drug (IND) tasks. Six of those INDs are ongoing and are centered on next-generation anticancer brokers, reviews the corporate.
The tasks characteristic next-generation nanomedicine-based anticancer brokers, underscoring its give attention to nanomedicine and giving it what it says is a aggressive edge within the rising discipline of nanotherapeutics. This collaboration strategically aligns with Trieu’s established monitor report in accelerating nanomedicine improvement and regulatory approval, reviews Oncotelic.
“This partnership is poised to be a game-changer for our improvement applications,” said Trieu. “The flexibility to entry a fast IND-enabling platform is essential for accelerating SAPU’s and Oncotelic’s improvement applications.”
Constructing Its Nanomedicine Chops
Whereas the cope with Medicilon may show game-changing, it is not the one manner Oncotelic is constructing its nanomedicine chops. The corporate is partnering with Mosaic ImmunoEngineering, transferring its clinical-stage necroptosis most cancers remedy property to the corporate.
Mosaic, recognized for its expertise in oncology drug approval, will advance these property, which leverage the corporate’s vascular disrupting brokers like CA4P to stimulate tumor-infiltrating lymphocyte (TIL) responses and anti-tumor immunity. This necroptosis-focused method significantly targets ocular oncology – together with difficult circumstances like uveal melanoma and retinoblastoma – and showcases Oncotelic’s dedication to addressing cancers with vital unmet medical wants.
Innovating At The Similar Time
If that is not holding Oncotelic busy sufficient, the corporate not too long ago rolled out its AI platform PDAOAI. The platform is designed to streamline doc search and evaluation to handle the rising wants of knowledge-based industries together with prescribed drugs and biotechnology. Oncotelic mentioned Sapu used PDAOAI to coach workers and implement normal working procedures (SOPs) enabling the ability to attain GMP compliance inside one yr.
Nanomedicine not solely holds promise in bettering affected person outcomes, but it surely’s additionally an enormous market alternative for Oncotelic. The worldwide nanomedicine market is projected to achieve $570.98 billion by 2032, rising at a CAGR of 11.7% from now till 2032. The corporate is making strikes – the most recent being its cope with Shanghai Medicilon – to steer on this space, innovating in oncology through developments in nanomedicine and focused immunotherapeutics, pushed by Trieu’s confirmed monitor report and scientific experience on this space.
Featured photograph by Towfiqu barbhuiya on Unsplash.This publish accommodates sponsored content material. This content material is for informational functions solely and isn’t meant to be investing recommendation.
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
